Form 4: Barinthus Biotherapeutics Executive Granted Share Options

Graham Griffiths, Chief Business Officer of Barinthus Biotherapeutics, receives options to purchase 200,000 ordinary shares.

Summary

• Graham Griffiths, the Chief Business Officer of Barinthus Biotherapeutics plc, was granted share options on February 3, 2025.
• The options allow Griffiths to purchase 200,000 ordinary shares at an exercise price of $1 per share.
• The options vest in three equal annual installments, starting on February 3, 2026.
• The options expire on February 3, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation practice. The grant itself doesn't indicate positive or negative performance, but rather an incentive structure.

Positives

• The granting of share options to the Chief Business Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Granting share options to executives is a common practice in the biotechnology industry to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including share options, are common in the biotech industry.
• Comparable companies like Moderna or BioNTech also use equity-based compensation to attract and retain talent.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the Chief Business Officer to drive company growth.
• Employees may see this as a sign of confidence in the company's future.

Key Dates